Working... Menu

Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines (KEd)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03155100
Recruitment Status : Recruiting
First Posted : May 16, 2017
Last Update Posted : January 8, 2019
Bristol-Myers Squibb
Hospital District of Helsinki and Uusimaa
Information provided by (Responsible Party):
Raija Silvennoinen, Helsinki University Central Hospital

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : June 21, 2020
  Estimated Study Completion Date : June 30, 2023